MedPath

Tagged News

ChatGPT Reduces Clinical Trial Screening Time from 40 Minutes to Under 3 Minutes, But Human Oversight Still Required

AIOncology
  • ChatGPT-4 demonstrated superior performance over ChatGPT-3.5 in screening patients for clinical trials, achieving 84% accuracy with better sensitivity and specificity balance.
  • Screening times were dramatically reduced from over 40 minutes per patient to 1.4-3.0 minutes with GPT-3.5 and 7.9-12.4 minutes with GPT-4, though costs ranged from $0.02-$0.27 per patient.
  • Both AI models showed high specificity but low sensitivity in identifying eligible patients, with GPT-4 having only 16% median sensitivity despite 100% specificity.
  • Researchers concluded that large language models should complement rather than replace manual chart reviews due to difficulties in identifying patients who meet all eligibility criteria.

Frazier Healthcare Partners Closes $1.3 Billion Fund for Early-Stage Biotech Investments

Oncology
  • Frazier Healthcare Partners has successfully closed a $1.3 billion venture capital fund specifically targeting early-stage biotechnology companies and startup creation.
  • The firm was one of the most active biotech investors in 2024, participating in 17 deals and leading nearly one-third of those transactions.
  • Recent successful exits include Scorpion Therapeutics' $2.5 billion drug sale to Eli Lilly and major acquisitions like Novartis' $3.5 billion purchase of Chinook Therapeutics.
  • The new fund launch comes amid declining biotech venture funding, which dropped from $7 billion to $4.8 billion in Q2 2025 according to HSBC Innovation Banking.

ImmuneOnco's CD47xCD20 Bispecific IMM0306 Advances to Phase II with Promising Efficacy in B-Cell Lymphomas

Oncology
  • ImmuneOnco Biopharmaceuticals completed first patient enrollment in Phase II clinical trial of IMM0306, the world's first CD47xCD20 bispecific molecule to reach clinical stage.
  • Phase I data demonstrated encouraging efficacy with 81.8% overall response rate in follicular lymphoma/marginal zone lymphoma patients when combined with lenalidomide.
  • IMM0306 showed favorable safety profile with no dose-limiting toxicities or cytokine storm toxicity observed across eight dose groups up to 2.0 mg/kg.
  • The company is pursuing multiple clinical development pathways including monotherapy and combination studies across various B-cell lymphoma indications.

Marengo Therapeutics Strengthens Leadership with Pfizer Veteran Dolsten and Oncology Expert Tabernero

Precision MedicineOncology
  • Marengo Therapeutics appointed former Pfizer Chief Scientific Officer Mikael Dolsten to its Board of Directors and renowned oncologist Josep Tabernero to its Scientific Advisory Board in July 2025.
  • Dolsten brings over 16 years of R&D leadership experience at Pfizer, where he oversaw more than 36 drug approvals including breakthrough oncology therapies.
  • Tabernero, Director of the Vall d'Hebron Institute of Oncology and former ESMO President, will advise on clinical development of Marengo's immunotherapies across multiple tumor types.
  • The appointments come as Marengo advances invikafusp alfa, which has shown encouraging clinical signals in PD-1-resistant tumors with a 63% disease control rate in TMB-H gastrointestinal cancers.

Chipscreen Biosciences Receives FDA IND Approval for Brain-Penetrant Aurora B Inhibitor CS231295

Oncology
  • Chipscreen Biosciences has received FDA IND approval for CS231295, a next-generation brain-penetrant Aurora B selective inhibitor for treating advanced solid tumors.
  • CS231295 represents the first compound of its design to enter clinical trials globally, targeting genetic vulnerabilities in hard-to-treat cancers including those with RB1 deletion.
  • The drug demonstrates strong blood-brain barrier permeability, offering significant therapeutic potential for both primary brain tumors and brain metastases.
  • CS231295 completed first patient enrollment in its Phase I trial in China in May 2025, with FDA approval now accelerating U.S. clinical development.

New Market Report Reveals Global Mycosis Fungoides Clinical Trial Landscape with Major Pharma Players

OncologyRare Disease
  • A comprehensive 2025 market report analyzes the global clinical trial landscape for mycosis fungoides, providing insights into trial distribution across regions and phases.
  • Major pharmaceutical companies including Pfizer, Bristol-Myers Squibb, Johnson & Johnson, and Novartis are actively participating in mycosis fungoides therapeutic development.
  • Recent clinical developments include Innate Pharma's durable responses with lacutamab and BioInvent's FDA Fast Track designation for BI-1808 in cutaneous T-cell lymphoma treatment.
  • The report covers enrollment trends over five years and provides strategic analysis for investment decisions in this rare cancer indication.

Inka Health Partners with OneMedNet to Develop AI-Powered External Control Arms for Cancer Drug Development

AIReal World EvidenceOncology
  • Inka Health has been selected by OneMedNet to lead a data analytics initiative using real-world data to develop external control arms as a faster, more cost-effective alternative to traditional clinical trials.
  • The project will deploy Inka Health's proprietary SynoGraph platform to build and validate an external control arm for the Keynote-189 trial of pembrolizumab in non-small cell lung cancer.
  • This collaboration aims to accelerate market entry for new cancer therapies by offering a more efficient path to generate evidence needed for regulatory and reimbursement approvals.
  • The initiative positions both companies in the rapidly expanding Real-World Evidence market, projected to exceed $4.6 billion globally by 2030.

AstraZeneca and Revna Biosciences Launch Targeted EGFR Therapy for Lung Cancer Patients in Ghana

Targeted TherapyPrecision MedicineOncology
  • AstraZeneca has launched a targeted therapy for EGFR-mutated lung cancer patients in Ghana through its strategic partnership with Revna Biosciences, marking a significant milestone in expanding access to precision oncology in sub-Saharan Africa.
  • The collaboration has operationalized EGFR biomarker testing within diagnostic workflows at leading cancer centers, enabling targeted therapy selection at the point of care and accelerating time-to-therapy for patients.
  • The partnership has established a comprehensive infrastructure that integrates advanced molecular diagnostics with personalized treatment pathways, while building real-time data integration capabilities for enhanced clinical decision-making.
  • This initiative represents a new standard of care for historically underserved patients in the region, combining cutting-edge diagnostics with access to targeted anti-cancer therapies to ensure patients receive appropriate treatment timing.

DX&VX Secures $220 Million mRNA Cancer Vaccine Licensing Deal with U.S. Biotech Partner

Oncology
  • DX&VX has signed its first global out-licensing agreement worth approximately $220 million with a U.S. biotech company for its proprietary mRNA-based cancer vaccine technology.
  • The agreement includes development milestones totaling $220 million plus sales-based milestone payments exceeding 10% of cumulative sales over 15+ years, with projected post-commercialization revenues potentially exceeding $940 million.
  • DX&VX will retain responsibility for leading R&D activities including preclinical studies and Phase 1-3 clinical trials, while the partner handles global regulatory approvals and commercialization.
  • The licensed mRNA cancer vaccine has demonstrated superior anticancer efficacy in preclinical animal studies compared to global competitors currently in Phase 2b trials.

LTZ Therapeutics Partners with Eli Lilly to Advance First-in-Class Myeloid Engager Platform

Oncology
  • LTZ Therapeutics announced a strategic research collaboration with Eli Lilly to develop novel myeloid engager therapeutics against selected targets for diseases with high unmet need.
  • The agreement includes a double-digit million USD upfront payment and equity investment for LTZ, plus eligibility for preclinical, clinical, regulatory and commercial milestone payments.
  • The collaboration combines LTZ's first-in-class Myeloid Engager Platform with Lilly's expertise in research, development and commercialization to accelerate therapeutic development.
  • LTZ's platform targets myeloid biology to improve clinical outcomes in patients with cancer and autoimmune diseases through novel immunotherapy approaches.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.